CTT Pharmaceutical (CTTH) CEO/Director Buys 10,100 Shares

What Happened

• The company's CEO and a director reported an open-market purchase of 10,100 shares of CTT Pharmaceutical Holdings, Inc. (CTTH) on 2026-09-22 at $0.04 per share (reported total ≈ $455). This is a purchase (a net acquisition) rather than a sale.
• The Form 4 was filed as an amendment. The filing corrects the insider's post-transaction holdings to 9,424,556 shares (the original filing listed an incorrect number).

Key Details

• Transaction date: 2026-09-22
• Transaction type: Purchase (code P) — open market/private purchase
• Price and quantity: 10,100 shares at $0.04 per share (reported total ≈ $455)
• Shares owned after transaction (corrected): 9,424,556
• Filing status: Amended Form 4 filed 2026-09-29; the amendment corrects the holdings figure. The filing was submitted about a week after the trade date (later than the typical 2-business-day Form 4 deadline).
• No indication in the filing of a 10b5-1 plan, option exercise, gift, or tax-withholding event.

Context

• Small-dollar insider purchases like this cost only a few hundred dollars and may carry limited informational weight for investors. The key takeaway is the purchase itself and the corrected holdings figure; the late/amended filing reduces near-term transparency but does not by itself indicate the insider’s motive.